STOCK TITAN

CureVac N.V. - $CVAC STOCK NEWS

Welcome to our dedicated page for CureVac N.V. news (Ticker: $CVAC), a resource for investors and traders seeking the latest updates and insights on CureVac N.V. stock.

CureVac N.V. (NASDAQ: CVAC) is a pioneering biopharmaceutical company based in Germany, known for its groundbreaking work in the field of messenger RNA (mRNA) technology. Founded in 2000 as a spin-off from the University of Tübingen, CureVac has developed a unique position as a leader in mRNA research and development. The company's core technology uses mRNA as a data carrier that instructs the human body to produce its own proteins capable of fighting a wide range of diseases, including cancer, infectious diseases, and rare genetic disorders.

CureVac's proprietary mRNA technology has a broad range of applications. In oncology, the company is developing both off-the-shelf and personalized cancer vaccines. Their off-the-shelf cancer vaccines target tumor antigens shared across different cancer types, while the personalized vaccines are tailored to individual patients based on their unique tumor profiles. CureVac has recently entered a collaboration with The University of Texas MD Anderson Cancer Center to further this mission.

In infectious disease, CureVac has partnered with pharmaceutical giant GSK to develop a suite of prophylactic vaccines. This includes second-generation COVID-19 vaccines and a promising seasonal influenza vaccine program. Recent Phase 2 interim data showed that CureVac's influenza vaccine candidates produce higher geometric mean titers against influenza A strains compared to licensed vaccines, though optimizations are ongoing for influenza B strains. Additionally, a new Phase 2 study has been initiated to further enhance the immune response against the relevant influenza B strain.

Financially, CureVac remains robust, with cash and cash equivalents amounting to €402.5 million at the end of 2023. The company's strategic initiatives, such as organizational redesign and partnerships, aim to extend this runway into the fourth quarter of 2025. As of late, CureVac has also achieved significant milestones in its clinical pipeline, which includes a move to Phase 2 studies for its H5N1 avian flu vaccine candidate and ongoing litigation to defend its intellectual property rights.

Overall, CureVac continues to push the boundaries of mRNA technology, with a deep clinical pipeline and strong collaborations to back its innovative discoveries. For more information, visit their official website at www.curevac.com.

Rhea-AI Summary

CureVac has commenced dosing of the first participant in a Phase 2 study for its multivalent seasonal influenza vaccine candidate, developed in collaboration with GSK. This follows interim data from a Phase 2 part of a combined Phase 1/2 study, which showed the vaccine candidate elicited stronger immune responses against influenza A strains but weaker responses against influenza B strains compared to licensed vaccines. The Phase 2 study's design has been updated to match the three flu strains recommended by the WHO, excluding the B/Yamagata lineage. The study will evaluate the safety, reactogenicity, and immunogenicity of the vaccine in 500 healthy adults, split between younger (18-64) and older (65-85) participants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
-
Rhea-AI Summary

CureVac (Nasdaq: CVAC) has announced its Q1 2024 financial results and business updates.

The company is in the process of an organizational redesign, reducing 150 positions by year-end to trim pandemic infrastructure and increase efficiency.

CureVac's pre-pandemic H5N1 vaccine, co-developed with GSK, received FDA Fast Track designation and is in Phase 1 development.

Settlements with Acuitas Therapeutics recognized CureVac’s patent claims, while ongoing litigation with Pfizer/BioNTech continues under seven U.S. patents, with a trial set for Q2 2025.

In Q1 2024, CureVac reported €300.2 million in cash, €12.4 million in revenue (up 74% YoY), and an operating loss of €73.3 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.53%
Tags
-
Rhea-AI Summary
CureVac announced financial results for Q4 and full-year 2023, highlighted by a strong cash position, strategic collaborations, positive clinical data in COVID-19 and flu vaccines, organizational redesign, and leadership appointments. Despite termination of the Pandemic Preparedness Agreement, the company extended its cash runway, signed a collaboration with MD Anderson, and progressed in avian flu studies. The appointment of Thaminda Ramanayake as Chief Business Officer aims to accelerate pipeline development and strategic partnerships.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.46%
Tags
Rhea-AI Summary
CureVac appoints Thaminda Ramanayake as Chief Business Officer, bringing over 15 years of experience in biopharma development and deal-making. Mr. Ramanayake's successful track record includes clinical collaborations, M&A, and strategic financing initiatives. He aims to accelerate the development of mRNA vaccines and medicines across various therapeutic areas at CureVac.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.46%
Tags
management
-
Rhea-AI Summary
CureVac initiates a Phase 1/2 study in collaboration with GSK to develop a pre-pandemic vaccine for the avian influenza (H5N1) virus, addressing a potential future pandemic threat. The study aims to assess the safety and efficacy of the vaccine candidate in healthy adults, utilizing CureVac's mRNA technology platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.46%
Tags
-
Rhea-AI Summary
CureVac N.V. (CVAC) will announce its fourth-quarter and full-year 2023 financial results and business updates on April 24, 2024. The company, a global biopharmaceutical firm focused on mRNA-based medicines, will host a conference call and webcast on the same day. Investors can access the call via various dial-in numbers or the live webcast link on the CureVac website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.06%
Tags
conferences earnings
Rhea-AI Summary
CureVac and MD Anderson have entered into a strategic collaboration to develop novel cancer vaccines. The agreement combines CureVac's mRNA capabilities with MD Anderson's research expertise to focus on hematological and solid cancers with high unmet medical needs. CureVac retains exclusive rights to late-stage development, commercialization, or partnering of the vaccine candidates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
none
-
Rhea-AI Summary
CureVac (CVAC) announces positive interim data from Phase 2 study of seasonal flu vaccine candidate in collaboration with GSK. The candidate showed boosted antibody titers against all encoded flu strains across age groups. Geometric mean titers for influenza A strains exceeded licensed comparator vaccines, while those for influenza B strains were lower but in line with expectations. The platform demonstrated an acceptable safety profile, with plans for further optimizations to enhance immune responses against influenza B strains.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.72%
Tags
-
Rhea-AI Summary
CureVac N.V. (CVAC) Announces Positive Interim Data from Phase 2 Study of COVID-19 mRNA Vaccine Candidates
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.84%
Tags
clinical trial covid-19
Rhea-AI Summary
CureVac N.V. (Nasdaq:CVAC) announced that the German Federal Patent Court denied the validity of its patent EP 1 857 122 B1 after a nullity action filed by BioNTech SE. The decision does not affect ongoing litigation in Germany regarding seven other intellectual property rights, covering foundational as well as COVID-19-specific mRNA innovation. CureVac plans to appeal before the German Federal Court of Justice, remaining confident in the strength of its broad intellectual property portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-29.55%
Tags
none

FAQ

What does CureVac N.V. do?

CureVac N.V. specializes in developing mRNA-based therapies and vaccines for various diseases, including cancer and infectious diseases.

Where is CureVac headquartered?

CureVac is headquartered in Tübingen, Germany.

Who are CureVac's notable partners?

CureVac has partnerships with GSK for vaccine development and The University of Texas MD Anderson Cancer Center for cancer vaccine research.

What are CureVac's recent achievements in vaccine development?

Recent achievements include positive interim Phase 2 data for their seasonal influenza vaccine and initiation of a new Phase 2 study to optimize responses to influenza B strains.

How is CureVac financially positioned?

CureVac had €402.5 million in cash and cash equivalents at the end of 2023 and aims to extend their financial runway into the fourth quarter of 2025.

What is the role of mRNA in CureVac's technology?

CureVac uses mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting diseases.

What are CureVac's focus areas in oncology?

CureVac focuses on developing off-the-shelf cancer vaccines and personalized cancer vaccines based on individual tumor profiles.

What are some challenges CureVac has faced?

Challenges include optimizing immune responses to influenza B strains and defending its intellectual property rights in litigation.

What recent collaborations has CureVac entered into?

CureVac has entered into a collaboration with The University of Texas MD Anderson Cancer Center to develop mRNA-based cancer vaccines.

What is CureVac's latest financial result?

CureVac reported significant progress in Q1 2024, including a robust cash position and ongoing cost management initiatives.

CureVac N.V.

Nasdaq:CVAC

CVAC Rankings

CVAC Stock Data

728.99M
118.65M
45.43%
23.8%
2.24%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Tuebingen